**What's Known**

*Streptococcus pneumoniae* is one of the major causative agents of meningitis in children. pneumococcal conjugate vaccine is one of the best methods to prevent pneumococcal disease.Pneumococcal capsular serotypes can vary in different geographical areas.

**What's New**

The first attempt to evaluate the most common capsular serotypes in northeast Iran.Considering common capsular serotypes in Bojnurd (Iran), PCV-13 vaccine is the suitable choice for a vaccination program.

Introduction {#sec1-1}
============

*Streptococcus pneumoniae* (*S. pneumoniae*) is a Gram-positive coccus that can colonize the nasopharyngeal area without major clinical symptoms. Clinical manifestation of the bacteria ranges from otitis media and sinusitis to bacteremia, invasive pneumonia, and meningitis. ^[@ref1]\ ,\ [@ref2]^*S. pneumoniae* causes more than 14 million cases of invasive infections and approximately one million deaths annually among children in developing and underdeveloped countries. During 1999-2010, in the Asian-Pacific region, the incidence of *pneumococcal* disease among children aged under two years was about 150 cases per 100,000. ^[@ref3]^

Meningitis is defined as the inflammation of meninges surrounding the brain and spinal cord. Infectious agents that cause bacterial meningitis are *S. pneumoniae*, *Neisseria meningitidis*, and *Hemophilus influenzae*. Of these, *S. pneumoniae* is the most common agent. It has various virulence factors such as streptolysin-O, IgA protease, and polysaccharide capsule. The bacterium has more than 90 capsular serotypes, but only a limited number is related to acute *pneumococcal* meningitis. ^[@ref4]^

The mortality rate due to meningitis among children and adults is 25-73% and 20-30%, respectively, and the survivors often suffer from neurological complications and sequelae. ^[@ref4]^ The adverse effect depends on the patient's medical condition such as the underlying chronic disease, immune system, nutrition, etc. ^[@ref5]\ ,\ [@ref6]^ Considering the high morbidity and mortality rates associated with *pneumococcal* infections, it is important to implement life-saving programs for the prevention, timely diagnosis, and treatment of *pneumococcal* diseases. As part of a national vaccination program, two types of vaccines are currently used in developed countries, namely *pneumococcal* capsular vaccine-10 (PCV-10) and *pneumococcal* capsular vaccine-13 (PCV-13). These vaccines contain serotypes \[1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F\] and \[1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F\], respectively.^[@ref7]^ The production of PCV-7, the previous type of PCV vaccine, has already been stopped.

In some developing countries, such as Iran, *pneumococcal* vaccination is not included in the national vaccination program. Therefore, data on serotypes causing invasive *pneumococcal* infections are not readily available since vaccination is carried out locally in Iranian public and private hospitals. ^[@ref4]\ ,\ [@ref8]^ Patients with suspected meningitis are typically viewed as emergency cases and physicians immediately proceed with empirical anti-microbial therapy and obtain cerebrospinal fluid (CSF) for laboratory evaluations. In some cases, the CSF culture could be negative while other tests (e.g. serological and molecular diagnostic) could be positive. Consequently, methods such as polymerase chain reaction (PCR) and multiplex PCR are also used. ^[@ref9]^

Since the prevalence of serotypes causing invasive *pneumococcal* infections varies in different geographical areas, we focused our study on patients suspected of meningitis in Bojnurd, Iran. Using the molecular method, we evaluated CSF samples for *pneumococcal* serotypes to recommend a regional vaccination program.

Materials and Methods {#sec1-2}
=====================

An observational and descriptive study of CSF samples from patients with suspected meningitis was conducted in the Laboratory of Imam Reza Hospital, Bojnurd, Iran. The samples were collected during 2014-2018 from children aged \<5 years with an increased level of C-reactive protein (CRP) or with fever and CSF leukocytosis. The samples were evaluated for *S. pneumoniae* using conventional methods, including CSF sediment gram staining, microscopic evaluation, and culture. The PCR assay was performed using *lytA* (N-acetylmuramoyl-L-alanine amidase) and *psaA* (*pneumococcal* surface adhesin A) as marker genes. In addition, capsular serotypes were determined using the modified Marimon's multiplex PCR method for wzy, wchE, and wciN beta genes.

The inclusion criteria were different physical examinations for children \<12 months and for those between 12 months and 5 years old, such as bulging fontanel, nuchal rigidity, and positive Brudziński signs. The general inclusion criteria were increased levels of CRP, CSF leukocytosis, CSF protein; reduced level of CSF glucose; and physical signs of fever, neck stiffness, vomiting, headache, etc. The exclusion criterion was a previous PCV vaccination. The data were analyzed with Pearson's Chi-square test using SPSS software (version 22.0). P\<0.05 was considered statistically significant.

The study was approved by the Ethics Committee of North Khorasan University of Medical Sciences, Bojnurd, Iran (code: 95/P/970). Written informed consent was obtained from the parents of the children.

*Genomic DNA Extraction* {#sec2-1}
------------------------

Total genomic DNA of the CSF samples was extracted using QIAamp® DNA Blood mini kit (QIAGEN, Germany). In accordance with the manufacturer's instruction, lysozyme at the concentration of 20 units/ml (SinaClon, Iran) was added to the lysis buffer. To obtain better results, based on a previous study, ^[@ref10]^ the CSF samples were centrifuged at 8,000 rpm for 3 minutes and then used as the precipitants for DNA extraction. ^[@ref10]^

*PCR Assay* {#sec2-2}
-----------

The PCR assay was performed using the TAKARA PCR thermal cycler Gradient TP600 (TAKARA, Japan). For all PCR reactions, EmeraldAmp® MAX PCR Master Mix 2X (Takara, Japan) in a volume of 50 µl was used.

*PCR Assay for Detection of S. pneumoniae* {#sec2-3}
------------------------------------------

The *lytA* and *psaA* genes were selected as marker genes for the detection of *S. pneumoniae*. PCR was performed with the following sequences: primary denaturation at 94 °C for 5 minutes, 35 cycles of amplification (denaturation at 94 °C for 30 seconds, annealing at 58 °C for 30 seconds, extension at 72 °C for 30 seconds), and a final extension at 72 °C for 7 minutes. ATCC® 33400 reference strain was used for PCR optimization and to determine the limit of detection (LOD) of the triplex PCR method. The third set of primers was added to the reaction as the internal control for preventing false-negative results. Specific primers were used as the control for the recognition of the human beta-globin gene. The list of primer sequences is described in [table 1](#T1){ref-type="table"}.

To assess the LOD, 10-fold serial dilutions (equivalent to 10^7^-10^1^ copies) of a *pneumococcal* reference strain ATCC® 33400 were prepared using tested sterile CSF as a solvent (due to the presence of human cells containing the beta-globin gene as the internal control) and the extracted DNA was tested by triplex PCR protocol. In positive reactions, the bands 268 (internal control), 187 (*lytA*), and 114 bp (*psaA*) were observed ([figure 1](#IJMS-45-125-g001.tif){ref-type="fig"}). In negative reactions, only the internal control band (268 bp) was observed ([table 2](#T2){ref-type="table"}). The primers were evaluated using the software packages AlleleID 6.0 (Biosoft International, Palo Alto, CA, USA) and Oligo 6.0 (Life Science Software Resource, Minnesota, USA). The reactions without any PCR product bands were false-negative and the results were not reliable ([table 2](#T2){ref-type="table"}). As shown in [figure 1](#IJMS-45-125-g001.tif){ref-type="fig"} and [table 3](#T3){ref-type="table"}, the mean LOD of the reaction after triplicate testing was between 101-102 colony-forming unit (CFU).

###### 

Primer sequences for detection of S. pneumoniae

  Primer                                           Sequence                            size                                    Reference
  ------------------------------------------------ ----------------------------------- --------------------------------------- ---------------------------
  *lytA* [1](#t1f1){ref-type="table-fn"} forward   5'-CCATTATCAACAGGTCCTACC-3'         187 bp[3](#t1f3){ref-type="table-fn"}   Present study
  *lytA* reverse                                   5'-TAAGAACAGATTTGCCTCAAG-3'                                                 
  *PsaA* [2](#t1f2){ref-type="table-fn"} forward   5'-GCCCTAATAAATTGGAGGATCTAATGA-3'   114 bp                                  Jourdain et al.^[@ref12]^
  *PsaA* reverse                                   5'-GACCAGAAGTTGTATCTTTTTTTCCG-3'                                            
  Beta-globin forward                              5'-GAAGAGCCAAGGACAGGTAC-3'          268 bp                                  Present study
  Beta-globin reverse                              5'-CAACTTCATCCACGTTCACC-3'                                                  

N-acetylmuramoyl-L-alanine amidase,

*S. pneumoniae* surface adhesin A precursor,

Base pair

![Agarose gel electrophoresis of triplex PCR on standard samples. The 268 bp, 187 bp, and 114 bp bands belong to beta-globin, *lytA, psaA* genes, respectively. Lanes, 1: 100 bp ladder; 2: 10^7^ copy; 3: 10^6^ copy; 4: 10^5^ copy; 5: 10^4^ copy; 6: 10^3^ copy; 7: 10^2^ copy; 8: 10^1^ copy of *S. pneumoniae* genome](IJMS-45-125-g001){#IJMS-45-125-g001.tif}

###### 

Interpretation of S. pneumoniae detection PCR results

  Interpretation      Beta-globin: 268 bp   *lytA*: 187 bp   *psaA*: 114 bp
  ------------------- --------------------- ---------------- ----------------
  Unacceptable        \-                    \-               \-
  *S. pneumoniae* -   \+                    \-               \-
  *S. pneumoniae* +   \+                    \+               \+

###### 

Determination of LOD using the PCR method

  Number   Standard   CFU   Result
  -------- ---------- ----- --------
  1        S1         107   \+
  2        S2         106   \+
  3        S3         105   \+
  4        S4         104   \+
  5        S5         103   \+
  6        S6         102   \+
  7        S7         101   \-

CFU: Colony-forming unit (mL)

The PCR was also performed on 51 clinical isolates of *S. pneumoniae* and all reactions tested positive for *lytA* and *psaA* genes; indicating 100% sensitivity. For the specificity evaluation, PCR was performed using the extracted DNA from *Haemophilus influenzae* (ATCC51907), *Neisseria meningitidis* (ATCC13077), *Staphylococcus aureus* (ATCC19323), *Streptococcus viridance* (ATCC6249), *Enterococcus fecalis* (ATCC29212), *Enterococcus faecium* (ATCC700221), *Escherichia coli*(ATCC25922), *Streptococcus agalactiae* (ATCC13813), *Listeria monocytogenes* (ATCC19115), *Pseudomonas aeruginosa* (ATCC10145), and *Mycobacterium tuberculosis* (ATCC25177). All reactions were negative.

*Multiplex PCR for Determination of Capsular Serotypes* {#sec2-4}
-------------------------------------------------------

The primers used for the amplification of various capsular types (*wzy, wchE,* and *wciN* genes) are listed in [table 4](#T4){ref-type="table"}. Marimon's method was modified and adapted to the conventional PCR and agarose gel electrophoresis settings. ^[@ref9]^ Originally, Marimon designed 55 sets of primers for evaluation with a capillary electrophoresis system. However, in the absence of such a system, due to the similar size of the PCR products of different primer pairs in the Marimon's method, we performed the evaluation with the conventional PCR and electrophoresis. The 55 pairs of primers were grouped into nine separate multiplex reactions based on the difference in their PCR product size. The optimum difference in size for detection in agarose gel electrophoresis was about 100 bp. In some cases, when grouping based on product size was not possible, the PCR products were evaluated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The PCR thermal cycling condition was 15 minutes at 95 ºC; 35 cycles of 60 seconds at 95 ºC, 60 seconds at 58 ºC, and 60 seconds at 72 ºC; and a final extension step of 10 minutes at 72 ºC.

###### 

Primer sequences for serotyping of S. pneumoniae

  Reaction                Serotype             Size (bp)                  Forward                     Reverse
  ----------------------- -------------------- -------------------------- --------------------------- --------------------------
  1                       14                   84                         CCGTCTTTTTGTATGGTGCTATG     TGAACAGCCAATCCATCAATCAG
  22A, 22F                181                  ACGTATAGGACGTTTCTCAATCC    ATCCCGAAACCAAATTGCTATCC     
  33C                     278                  CGGCAGGTATAAGTATTATCGG     CCTACACCTCTTATAAACGTTGG     
  35F, 47F                375                  TTGCTACAGTTTTGATGTATCTCC   AGAATCCGTTTCATCATACAGCC     
  6C, 6D                  473                  GTCGTGTAAAGTAGTATACAATCC   ATAATCCTCTGGATTATCCACCC     
  24A, 24B, 24F           569                  TCATGCTTATGTTATGTGTTACGG   GTGAGAGCTATATTTAGAACATGG    
  23B                     650                  TTGCATATGGATTTAATGGTGGG    ACCATTGCTGATAGAAGTAGAGG     
  2                       8                    94                         ATTAGCTGCATACGCAAGAACC      ATTAGCTGCATACGCAAGAACC
  3                       191                  AGAAATGCTATCCGCGTTGGG      TTGTCACGAGATTACGCTCAGG      
  20                      292                  TATTGTTCCGAAAAAAGAGTGGG    TACTCAAAGATTGTGTGGTACGG     
  11B, 11C                392                  TAGAAATCGCAAGATAGCCTTCC    CTGATTATGAGCATAGTTGATCC     
  7A, 7F                  491                  TTGACTGCAAGTGTTTCAATGGG    AAAGCACAAAATATTGGAACGAGG    
  28A, 28F                578                  AGGTAGACTACCAATTTCAATTCC   TACACCTGCTAATATCAATGTTCC    
  3                       7B, 7C, 40           101                        TTATTTTTTAGAAACATTAAAACTC   AACAATCATCTCTATTCGACC
  15B, 15C                201                  CGGATGATTGTAGCGTTTTATCC    ACTGTAGATTGTGTTCTGATTCC     
  31                      301                  TTTCAAGGATATGATAGTGGTGG    TAGCATTACAGATGTCACTAAGG     
  17F                     402                  TCTTGTCAAATACATACTTACCCC   GTAGTCTCGCATTTCTATCATCC     
  16A                     501                  GTTATGATAATGGTAACGCCTCC    CAGCCAATAAGTCATATACGCC      
  15A, 15F                598                  ATGAGAGGAAGATATATACTGGG    AAATAAGTTGTCCCATAGGAAGG     
  4                       9L, 9N               111                        CACTGTTGGCTATGTTAGCCTC      CTCTCCACGTGGCCAATATAC
  6A, 6B, 6C, 6D          211                  GAAGTAGAAAATCGTGTAAGTGG    TCCAACAACTAACCTTATAAGGG     
  23A                     314                  CTAGGTTCGTATCTCTTTGCGG     TACCAAATGGGTAATGGAGGGG      
  41A, 41F                413                  AGTTACTGGCCCTTTCTTATTCC    AGGTAAAAAGTCATATCCATTCCC    
  19F                     523                  TGTTCTTAGTAATGGATATACGGG   AAAACTTCACCAGGATCTAATGG     
  17A                     615                  TTTACCCAAGAATGGTTTCTAGG    AGCATAACAGTTTGCGCTATTGG     
  5                       21                   122                        TTATGCTGGTTTAAATATCGCTCC    TAACAAATATGCCAAAACGTAGCC
  34                      130                  TGTAAGAGGAGATTATTTTCACCC   GTCACAATAAAAACTGTACCTCC     
  25A, 25F, 38            140                  CAACACAATGTCTTATTGCAGCC    AACGCACCCCAAAATAACTTTCC     
  27                      240                  AATGCCGACGATTAATGCAGCC     CTAGCCATGCTGGATATTTCCC      
  19B, 19C                338                  TCAGTACGAATAGATGGAACACC    CCCAGTATCTAAATCCTAATCCC     
  4                       433                  ATTCAGAGGCAGCTAGTTCAGG     CAGAAGCTACTGTTAGGCTGG       
  48                      532                  CCCTTTGATAGCTATAGTATCGG    CCCTGGAATAGAAGTTTTCTAGG     
  12A, 12B, 12F, 44, 46   627                  CCTTTCTGATTCGTCCAGTTCC     AGTTGAACCAACTCCCCATCC       
  6                       10A, 10B, 0C, 10F    151                        CRATGAGGCTATATGTTGGAATAG    GTATTGAACYCATAGATAACAGAG
  29                      251                  TGTGGCAAAAATTTCTTTAGCGG    ATATACCCAGTAAACAGACAAGG     
  11A, 11D, 11F           348                  GGACATGTTCAGGTGATTTCCC     TGCGCCAAATTTGGTATCGACC      
  5                       443                  TTATCTATTTTATCGCAGACTCCC   CTGCCGATAAAAAGATAGATGCC     
  39                      544                  TATGAGGTATCATTTAGCAGGGG    ATCATCGAAATGGCAACTAAAGG     
  33B, 33D                640                  ACAACAGCAATGTTGTTGTTACTC   GAGAAGTAAGAGTTTTGTCATCC     
  7                       43                   160                        GGAATAGTTTAGGATTTGTACACC    TAGAGTCTGCTAACTGTAATATCC
  23F                     260                  TTCACAAGTGATAGTGAACTTGG    TATTAGCTTTATCGGTAAGGTGG     
  32A, 32F                357                  CTTACAATGAGACGCTATTTTCC    GTTATTACCATTGAATTCGTTCCC    
  33A, 33F, 37            453                  ATGTTAGATTAGATGGTTTGCTGG   ATTCAACACATAAACCGTTGGGG     
  1                       555                  TTTGCTAGATGGTGAGTTTGTATC   TTTAGAAGCTGCATTGTACTACTC    
  36                      230                  TTCCGGATCTATTCAATTTCCCC    CAATAACAGCCTCCGTTTTACC      
  2                       383                  GTTCAATATTTCTCCACTACACC    CTAAGAGTTCCAATACGTTGACC     
  35B                     483                  CATTAGTGTTGCTATGTTGTTCC    GATTAGATAAATAAATACGCCCCC    
  16F                     606                  ACTGCTTGCATATTAGCTTTATGG   TGATAGAGTGACAGAACAATTGG     
  8                       9A, 9V               172                        GATCAATGGCAACTATATTTACCC    GATTCACTGTCTGACTTTGAACC
  19A                     269                  ATTGGAGTAGCTGAGGTTTTTGG    TATCCAATTTAAAACCAGCACGG     
  35A, 35C, 42            367                  TCGTTCACCTACTTTATTAATGCC   AATAATTCCTAATACCATCTGCCC    
  45                      463                  CAGATTGGTTTTCACATCACTCC    ACATAACACGACTTTTAGTGACC     
  9                       18A, 18B, 18C, 18F   220                        AGTCTTACTAGACGTAATGAACC     AAGATAAATTGACTAAGTCCTCCC
  13                      328                  TTAACAGGTAGATTACGACTTGG    ATATCCCAAAAACAAAATCGCTGG    
  47A                     423                  AATACATTGTACGTCTTTAACCCC   CGAAGAATTAAACCCACATAACC     

bp: Base pair

Results {#sec1-3}
=======

Out of the 901 CSF sample, 92 cases tested positive for *S. pneumoniae* in culture and 106 cases tested positive for *lytA* and *psaA* genes using the molecular detection method. It should be noted that all the 92 culture-positive samples also tested positive in PCR. Of the 106 (11.8%) positive samples, 50 (47.2%) and 56 (52.8%) isolates were from female and male patients, respectively. There was no significant correlation between sex and *S. pneumoniae* isolation (P=0.92). Based on the primer pair combinations in [table 1](#T1){ref-type="table"}, all positive samples were evaluated for capsular serotypes using the modified Marimon's multiplex PCR method. As shown in [figure 2](#IJMS-45-125-g002.tif){ref-type="fig"}, the types 23F, 19F, 19A, 1, 14, and group six were the most common serotypes and groups in our samples. It should be noted that 2.8% of the samples were Non-typable (NT). The results for capsular serotypes and their distribution are presented in [figure 2](#IJMS-45-125-g002.tif){ref-type="fig"} and [table 5](#T5){ref-type="table"}.

![Serotype distribution among *S. pneumoniae* strains.](IJMS-45-125-g002){#IJMS-45-125-g002.tif}

###### 

Serotype distribution among S. pneumoniae strains in different years

                                                     2014-2015n (%)   2015-2016n (%)     2016-2017n (%)     2017-2018n (%)   Totaln (%)   
  -------------------------------------------------- ---------------- ------------------ ------------------ ---------------- ------------ -----------
  Number of *S. pneumonian* \[+, %\]                 160 \[16, 10\]   163 \[19, 11.7\]   278 \[29, 10.4\]   300 \[42, 14\]   901          
  *S. Pneumoniae* +[a](#t5f1){ref-type="table-fn"}   16 (15.1)        19 (17.9)          29 (27.4)          42 (39.6)        106 (11.8)   
  Women[b](#t5f2){ref-type="table-fn"}               10 (62.5)        8 (42.1)           16 (55.2)          16 (38.1)        50 (47.2)    
  Men[b](#t5f2){ref-type="table-fn"}                 6 (37.5)         11 (57.9)          13 (44.8)          26 (61.9)        56 (52.8)    
  Serotype[c](#t5f3){ref-type="table-fn"}            23F              3 (15)             5 (25)             4 (20)           8 (40)       20 (18.9)
  19A                                                2 (15.4)         3 (23.1)           4 (30.8)           4 (30.8)         13 (12.3)    
  19F                                                4 (23.5)         3 (17.6)           5 (29.4)           5 (29.4)         17 (16)      
  18C                                                0                1 (25)             1 (25)             2 (50)           4 (3.8)      
  6A/B                                               3 (21.4)         2 (14.3)           4 (28.6)           5 (35.7)         14 (13.2)    
  15B/C                                              0                0                  1 (50)             1 (50)           2 (1.9)      
  14                                                 1 (11.1)         2 (22.2)           2 (22.2)           4 (44.5)         9 (8.5)      
  9A/V                                               1 (20)           1 (20)             1 (20)             2 (40)           5 (4.7)      
  15A/F                                              0                0                  0                  1 (100)          1 (0.9)      
  7A/F                                               0                0                  0                  2 (100)          2 (1.0)      
  1                                                  2 (18.2)         1(9.1)             4 (36.4)           4 (36.4)         11 (10.4)    
  11A/D/F                                            0                0                  2 (66.6)           1 (33.3)         3 (2.8)      
  22A/F                                              0                0                  0                  2 (100)          2 (1.9)      
  NT                                                 0                1 (33.3)           1 (33.3)           1 (33.3)         3 (2.8)      

Number of positive cases;

Number of positive cases in female or male patients;

Number of positive cases of each serogroup or serotype; NT: Non-typable

Discussion {#sec1-4}
==========

Serotypes 23F, 19F, 1, 14, 19A, and serogroup 6 were the most common types in Bojnurd, Iran. PCV13 had the optimal coverage for children aged ≤5 years in this area. The Quellung reaction (Neufeld test) is the accepted gold standard method for *S. pneumoniae* serotyping. However, a number of factors (e.g., costs, the need for operational expertise, potential false-negative cultures especially in meningitis cases) hindered its use in clinical laboratory settings. ^[@ref11]^ Molecular assays have recently been developed to identify the invasive *pneumococcal* disease (IPD) associated with serotype distribution. ^[@ref9]\ ,\ [@ref12]^ Consequently, we used the modified Marimon's molecular method for serotyping *S. pneumoniae*. A limited number of capsular serotypes were related to most of the IPDs. ^[@ref13]^ In the present study, we found 13 serotypes, which were responsible for all meningitis cases. Note that 2.8% of the isolates were NT.

During the last two years, the prevalence of some serotypes (9A/V, 15A/F, 7A/F, 1, 11A/D/F and 22A/F) has increased in Bojnurd, Iran. Studies in the USA, UK, and Brazil have reported that only a few *pneumococcal* serotypes were related to the colonization and invasive diseases, ^[@ref14]\ -\ [@ref16]^ whereas a wide variety of such serotypes were identified in Asia. ^[@ref17]\ ,\ [@ref18]^ The serotypes 23F, 14, 19F, and 6B were predominant in East and Southeast Asia prior to the PCV vaccination. ^[@ref3]^ Several studies have reported that serotypes 1, 4, 6A/B, 7F, 9V, 14, 15B/C, 18C, 19F, 19A, and 23F account for more than 80% of the IPD in children, especially in developing countries without any routine *pneumococcal* vaccination programs. ^[@ref19]\ -\ [@ref22]^ In the absence of such programs in Iran, we managed to identify the presence of serotypes 23F, 19A, 19F, 18C, 14, 1, and serogroups 6A/B, 15B/C, 9A/V, 15A/F, 7A/F, 11A/D/F, and 22A/F. In line with other studies, ^[@ref1]\ ,\ [@ref4]\ ,\ [@ref23]\ -\ [@ref26]^ we found that the most prevalent serotypes in meningitis cases were 23F, 19A, 19F and 6A/B, which could be controlled with the PCV-13 vaccine. In contrast, Talebi and colleagues reported that the most common serotypes in *pneumococcal* isolates were 14 and 3, followed by 23F and 19F. ^[@ref27]^

Some researchers believe that the common serotypes in infants are different from those found in adults. A previous study reported that the serotypes 6 and 19 were common in IPD related isolates and the 23-valent vaccine was best for adults. ^[@ref28]^ Moreover, in another study, they reported serotype 6 was most prevalent in adults, but serotype 19 in infants. ^[@ref29]^ Dashti and colleagues reported that the most prevalent serotypes were 19, 6, 14, 17, 20, 23, and 21 in nasopharyngeal carriers under 10 years old in Tehran (Iran). ^[@ref30]^ Another study reported that four serotypes of 19A, 6, 3, and 23F were common in both the carrier and clinical samples at a rate of at least 91%. ^[@ref13]^ Gharailoo and colleagues reported that the serotypes 6A/B, 19A, 19F, and 23F were the common types of nasopharyngeal carriers, ^[@ref31]^ whereas another study reported that the most common serotypes in nasopharyngeal carrier children were 19F, 6A/B, 15A, 11, 23F, 1, 19A, and 35B. ^[@ref32]^ Based on the above-mentioned studies, we deduced that the source of meningitis related to *pneumococcal* serotypes was the nasopharyngeal area. Overall, the data showed that serotypes 6A/B, 14, 18C, 19F, 19A, and 23F were the most prevalent serotypes in Asia, especially in non-immunized areas.

We found that PCV-13 vaccine is the best candidate against common serotypes of meningitis-related *S. pneumoniae* strains. This vaccine is readily available in Iran and covers 77.13% of the most common serotypes in our region, especially 23F, 19A, 19F, and 6A/B. On the other hand, PCV-10 vaccine covers 65.06% of the serotypes but excludes the two major serotypes 19A and 6A. None of these vaccines could cover serotypes 22, 7, 15A/F, 15B/C, and 11. The present study was the first attempt to identify the distribution of serotypes in Bojnurd. Serotyping on more specimens is recommended to determine the extent of their coverage and evaluate the effectiveness of the vaccine.

Conclusion {#sec1-5}
==========

The high pathogenicity of *S. pneumoniae* in different age groups and the increasing antimicrobial resistance are alarming. The management of this pathogen is essential to protect lives and to reduce therapeutic treatment costs. PCV-13 vaccine is the preferred choice in northeast Iran. More research on serotypes in different geographical regions allows the design of a nationwide vaccination program. Further studies on capsular serotyping, antimicrobial susceptibility testing, and molecular epidemiology should provide a better understanding of common *pneumococcal* types and allow choosing optimal therapeutic strategies in Iran.
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